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Genetic variants are implicated in the development of amyotrophic lateral sclerosis (ALS), but it is un-
clear whether the burden of rare variants in ALS genes has an effect on survival. We performed whole
genome sequencing on 8 familial ALS (FALS) patients with superoxide dismutase 1 (SOD1) mutation and
whole exome sequencing on 46 sporadic ALS (SALS) patients living in Hong Kong and found that 67% had
at least 1 rare variant in the exons of 40 ALS genes; 22% had 2 or more. Patients with 2 or more rare
variants had lower probability of survival than patients with 0 or 1 variant (p ¼ 0.001). After adjusting
for other factors, each additional rare variant increased the risk of respiratory failure or death by 60%
(p ¼ 0.0098). The presence of the rare variant was associated with the risk of ALS (Odds ratio 1.91, 95%
conﬁdence interval 1.03e3.61, p ¼ 0.03), and ALS patients had higher rare variant burden than controls
(MB, p ¼ 0.004). Our ﬁndings support an oligogenic basis with the burden of rare variants affecting the
development and survival of ALS.
 2017 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Amyotrophic lateral sclerosis (ALS) is characterized by the
degeneration of motor neurons, progressive paralysis, and death.
The world-wide incidence of ALS is 0.3e7.0 per 100,000 per year
(Cronin et al., 2007) and in Hong Kong, the incidence of ALS was
estimated to be 0.6 per 100,000 per year (Fong et al., 2005). Five toenetics, Zhongshan School of
cal Science and Technology
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Inc. This is an open access article10% of cases are familial. There are more than 20 known
causative genes, withmore showing associationwith risk of disease
(Leblond et al., 2014). Mutations in superoxide dismutase 1 (SOD1)
and chromosome 9 open reading frame 72 (C9ORF72), the 2 most
common causes of familial ALS (FALS) in populations of European
ancestry, account for about half of familial cases collectively
(Finsterer and Burgunder, 2014). Mutations in ALS genes are also
found in 10% of patients with sporadic ALS (SALS) (Renton et al.,
2014). While twin studies from European populations showed
ALS heritability to be around 61% in sporadic cases (Al-Chalabi et al.,
2010), genome-wide association analyses showed that common
single nucleotide polymorphisms (SNPs) contribute to 8.5%e12% of
SALS’s heritability (Fogh et al., 2014; van Rheenen et al., 2016). The
difference in these heritability estimates, or “missing heritability,”
suggests that there is a notable genetic role in ALS that remains to
be elucidated.
There is considerable variability in ALS phenotype: age and site
of onset, relative degree of upper and lower motor neuron
involvement, and rate of progression (Swinnen and Robberecht,under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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SOD1 mutation with considerable intrafamilial phenotypic vari-
ability (Fong et al., 2006; Ng et al., 2008). Identiﬁcation of patients
with mutations in more than 1 gene has led to the hypothesis of an
oligogenic model of ALS, with 4.0% of FALS and 1.3% of SALS patients
carrying multiple variants in 1 study (Kenna et al., 2013). Patients
harboring rare variants in more than 1 gene had disease onset 10
years earlier than subjects with variants in a single gene (Cady et al.,
2015). We, therefore, hypothesized that there is an oligogenic in-
ﬂuence on survival in familial and SALS. We characterized the
presence and burden of rare variants in 40 ALS genes in 8 FALS and
46 SALS patients.
2. Patients and methods
2.1. Subjects
ALS patients diagnosed and followed up at QueenMary Hospital,
Hong Kong since 1997 were enrolled. They all fulﬁlled the criteria
for deﬁnite ALS, probable ALS, or probable ALSelaboratory-sup-
ported based on the revised El Escorial criteria (Brooks et al., 2000).
2.1.1. Familial ALS
Eight ALS patients from 4 Chinese families in Hong Kong were
included. They have been previously conﬁrmed to harbor
c.449T>C:p.I150T SOD1 mutation. Five (F19, F21, F204, F310,
and F331) came from the same kindred (Supplementary Fig. 1). FA-
III-16, FB-III-9, and FC-I came from 3 different families in Hong Kong.
2.1.2. Sporadic ALS
Forty-six SALS patients were included. Information on sex, age,
and site of onset, treatment with riluzole, and survival as deﬁned by
time from symptom onset to ventilation (noninvasive or invasive)
or time to death (non-ventilated subjects), whichever is earlier,
were recorded. We measured survival in terms of time from
symptom onset to ventilatory failure or death, whichever is earlier,
to avoid the confounding effect of ventilatory support on survival.
Genetic relatedness was measured by pi-hat.
2.1.3. Controls
A total of 699 exomes from volunteer-based healthy controls in
Hong Kong were used for case-control association tests. Whole
exome sequencing (WES) was performed using Illumina TruSep
Exome capture kits with 48 coverage overall followed by the same
procedures as ALS subjects. Only protein-coding regions were
included for downstream analyses. Principal component analysis
was performed to check the population stratiﬁcation between ALS
and control (Chang et al., 2015; Yang et al., 2011).
2.2. Patient consents
This study has been approved by the Hong Kong Hospital Au-
thority/Hong Kong West Cluster Institutional Review Board Ethics
Committee and all participants gave written informed consent to
participate.
2.3. Genotyping and rare variants ﬁltering
Whole genome sequencing (WGS) was performed on 8 FALS
patients and WES was performed on 46 SALS patients using Nim-
blegen SeqCap EZ Human Exome Kit v3.0 capture kits. Illumina
Hiseq 2000 system with 100 bp pair-end reads was used on both
WGS and WES. The sequencing coverage reached at least 33 and
95, respectively. The GATK (The Genome Analysis Toolkit) best
practices pipeline was adopted for sequencing data processing andvariant calling analysis (McKenna et al., 2010). Another independent
sample in the same sequencing batch consisting of 28 controls from
the same population, using the same capture kits and sequencing
machine, was used to ﬁlter out any potential batch effect and
system bias. Variant annotation and ﬁltering were performed by
KGGSeq (Hsu et al., 2016; Li et al., 2012). As ALS is a rare disease,
only nonsynonymous variants withminor allele frequency (MAF) of
less than 0.1% across all populations in Exome Aggregation Con-
sortium (ExAC) dataset were selected (http://exac.broadinstitute.
org). All of the variants had a sequencing quality score (Phred) of
at least 50 and a mapping quality score of at least 20. Only those
alternative alleles with more than 25% of total reads were consid-
ered as heterozygous alleles. Phred-scaled p-value using Fisher’s
exact test (FS) was less than 60, which excluded strand bias.
2.4. ALS candidate genes
Forty protein-coding genes: 14 causative ALS genes, 24 suscep-
tibility risk genes (Leblond et al., 2014), and 2 recently described
genes from a large-scale ALS exome study (Cirulli et al., 2015) were
examined for novel and rare variants (Supplementary Table 1).
2.5. Survival analysis
The Kaplan-Meier survival analysis was used to measure the
effect of rare variant burden on the time to ventilator or death. We
deﬁned the patients started on noninvasive ventilatory support
(NIV) as reaching the endpoint of ventilatory failure since in our
center, NIV support was only initiated in patients with respiratory
failure. All but 1 patient who received NIV had expressed their wish
against intubation, and none of them would have survived much
longer without NIV support. After adjusting for onset age, censor-
ship, sex, onset region, inheritance (familial or sporadic), and rilu-
zole treatment, Cox regression was performed to estimate the
proportional hazard ratio of rare variant burden on survival.
2.6. Rare variant association test
Rare variant association tests between case and control were
performed by RVTESTS (Zhan et al., 2016) and KGGSeq-integrated
SKAT package (Ionita-Laza et al., 2013) on 3 levels: single variant,
gene, and gene set. Collapsing and combining rare variants followed
by Fisher’s exact test (CMCFisher), upweighing rare variant using
inverse frequency from controls (Madsen-Browning), and
Sequencing Kernel Association Test (SKAT and SKATO) were
selected to evaluate rare variant burden association.
3. Results
3.1. Familial ALS
The mean (SD) age of onset of the 8 FALS patients (3 males, 5
females) was 41.4 (8.71) years. Only F19 had bulbar onset. Six
subjects reached the endpoint of requiring ventilatory support or
death after a median survival of 30.5 (interquartile range 11e68)
months (Table 1).
Survival timewas largely variable in the8 familial patients among
the4 kindredswehave analyzed. From the samekindred, F19had the
shortest survival of 3months, followed by F21 and F204 (11months).
F310 and F331 had longer survival of 37 (and still alive) and
74 months, respectively. FA-III-16, FB-III-9, and FC-I, from 3 different
families, had longer survival of 76, 50, and 80 months respectively.
In the exons of 40 ALS genes, F19 had 2 additional rare variants:
ALS2 p.L520F and DAO p.P103L (Table 2; Supplementary Table 2).
F21 had 1 additional rare variant in DAO (p.P103L). F204 had 1
Table 2
Rare single nucleotide variants detected among 40 ALS genes in ALS patients
Gene Mutation Minor allele frequency Database,
ALSoD/alsdb
A
OALS (n ¼ 54) Control
(n ¼ 699)
ExAC
(n ¼ 60,706)
Rare mis-sense SNVs in familial ALS patients
ALS2 p.L520F 0.019 0.004 0.000098 /
NEK1 p.P287A 0.056 0.012 0.0001 /
SETX p.M2324I 0.019 0 0.00002 / $
DAO p.P103L 0.037 0.004 0.00036 /
SOD1 p.D93G 0.019 0 0.00001 þ/ $
SOD1* p.I150T 0.148 0 N / $
C9orf72a p.G465R 0.019 0.0019 0.00009 /
Rare mis-sense SNVs in sporadic ALS patients
TARDBP p.G298S 0.037 0 N þ/þ $
TARDBP p.M337V 0.019 0 N þ/þ $
TARDBP p.S375G 0.019 0 0.00002 /þ $
KIFAP3 p.F694L 0.019 0.006 0.00007 /
DCTN1 p.D1199N 0.038 0.007 0.00015 /
DCTN1 p.G1013A 0.019 0 0.00001 / $
DCTN1 p.Q701R 0.019 0.009 0.00047 /
DCTN1 p.A457T 0.02 0 0.00004 / $
PLCD1 p.M412R 0.019 0 0.00007 / $
NEK1 p.L413P 0.019 0.006 0.00011 /
NEK1 p.P287A 0.056 0.012 0.0001 /
ARHGEF28 p.A168T 0.019 0 N / $
ARHGEF28 p.A717V 0.019 0.001 0.000196 / 1
ARHGEF28 p.G1029W 0.019 0 N / $
ARHGEF28 p.M1261T 0.019 0 0.00002 / $
SQSTM1 p.V144I 0.019 0 0.00006 / $
SQSTM1 p.G411S 0.019 0 0.00005 /þ $
PON2 p.S31F 0.019 0.002 0.00002 / 1
VCP p.G157R 0.019 0 N / $
SETX p.N1100S 0.019 0 0.00001 / $
SETX p.M627T 0.019 0.004 0.00012 /
ITPR2 p.M2443T 0.019 0.007 0.000196 /
ITPR2 p.V1952A 0.019 0 0.00001 / $
PRPH p.L118M 0.043 0.023 0.000397 /
TBK1 p.L94S 0.019 0 N / $
TBK1 p.H336R 0.019 0 N / $
DAO p.T269I 0.019 0 N / $
ATXN2 p.A1023V 0.019 0 0.00007 / $
APEX1 p.G8R 0.019 0.003 0.00012 /
APEX1 p.E110G 0.019 0 0.00001 / $
SPG11 p.L1982S 0.019 0.025 0.000699 /
SPG11 p.P194L 0.019 0.005 0.00007 /
UNC13A p.P960S 0.019 0 N / $
NEFH p.T642M 0.019 0.025 0.00085 /þ
Key: ALSdb, (http://alsdb.org/index.jsp, Last Update: Oct 2016); ALSoD, (http://alsod.iop.k
ExAC, Exome Aggregation Consortium V3; N, Novel variant in ExAC; OR (95% CI), Odds rati
are reference homozygous.
*p value <0.0001.
a This SNV has been excluded from downstream analyses since only 74.8% of control
b Fisher’s exact test.
c Alive.
Table 1
Demographics of FALS and SALS patients
Total number of ALS FALS (8) SALS (46)
Mean age of onset (y) (SD) 41.4 (8.71) 58.1 (13.45)
Ethnic Chinese 8 (100%) 44 (95.7%)
Male sex 3 (37.5%) 28 (60.9%)
Bulbar onset 1 (12.5%) 20 (43.5%)
Riluzole use 0 2 (8.7%)
Surviving patients 2 (25%) 6 (13.0%)
Median Time to ventilator/death (mo) (IQR) 30.5 (11e68) 34 (13e42)
Number of healthy controls 699
Male sex 305 (44%)
Mean age 55.5 (8.27)
Key: ALS, amyotrophic lateral sclerosis; FALS, familial ALS; IQR, interquartile range;
SALS, sporadic ALS; SD, standard deviation.
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excluded this variant from the downstream survival and case-
control association analyses because only 74.9% of the control
subjects had adequate coverage for this locus (vs.100% of cases). FB-
III-9 had 3 additional rare variants (NEK1 p.P287A, SETX p.M2324I,
and an additional SOD1 variant p.D93G). In contrast, F331 and FA-
III-16 who survived for more than 70 months, and the 2 surviving
subjects (F310, FC-I), had no additional rare variant. Overall, FALS
patients with 2 or more rare variants appear to have shorter time to
ventilator dependence or death.
3.2. Sporadic ALS
The mean (SD) age of onset in SALS was 58.1 (13.45) years
including censored patients, and 60.9% of the patients were male
(Table 1). Twenty patients (43.5%) had bulbar onset. Two patientsLS versus control,
R (95%CI)b
p valueb SampleID Survival
4.36 (0.08e55.41) 0.258 F19; 3
5.05 (0.84e21.88) 0.038 FB-III-9 50
$ $$ FB-III-9 50
8.50 (0.70e75.88) 0.047 F19; F21 3; 11
$ $$ FB-III-9 50
$ $$ F19; F21; F204; F310; F331;
FA-III-16; FB-III-9; FC-I
3; 11; 11; 37c;74;
76; 50; 80c
9.79(0.12e770.67) 0.178 F204 11
$ $$ MND_19; MND_40 18; 10
$ $$ MND_4 164
$ $$ MND_37 15
2.96 (0.06e30.59) 0.337 MND_64 3
5.42 (0.50e34.11) 0.081 MND_17; MND_72 13; 49c
$ $$ MND_60 72c
2.17 (0.05e18.42) 0.408 MND_58 11
$ $$ MND_34 72
$ $$ MND_17 13
3.27 (0.07e33.81) 0.311 MND_37 15
5.05 (0.84e21.88) 0.038 MND_51; MND_64 38; 11
$ $$ MND_58 11
2.70 (0.16e997.92) 0.142 MND_8 83
$ $$ MND_54 48
$ $$ MND_14 44
$ $$ MND_47 42
$ $$ MND_49 24
1.60 (0.15e912.09) 0.154 MND_57 34
$ $$ MND_73 40c
$ $$ MND_24 12
4.36 (0.08e55.41) 0.258 MND_59 31
2.53 (0.05e23.25) 0.37 MND_24 12
$ $$ MND_37 15
1.98 (0.21e9.04) 0.302 MND_18; MND_52 1; 20
$ $$ MND_51 38
$ $$ MND_47 42
$ $$ MND_25 12
$ $$ MND_32 41
6.54 (0.11e127.61) 0.2 MND_74 19c
$ $$ MND_10 37
0.76 (0.02e5.02) 1.000 MND_55 24
3.95 (0.07e50.28) 0.279 MND_39 42
$ $$ MND_25 12
0.78 (0.02e5.19) 1.000 MND_55 24
cl.ac.uk/, Last Update: Sep 2015); DB, the variant has been reported in ALS database;
o with 95% conﬁdence interval; SNV, single nucleotide variant; $$, All control subjects
had adequate coverage.
Fig. 1. Kaplan-Meier survival curves for ALS patients stratiﬁed by nonsynonymous and synonymous rare variants. The differences were evaluated by the log-rank test with 2 degrees
of freedom. Abbreviations: RV, rare variant; N, number of patients.
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the endpoint after a median of 34 (interquartile range 13e42)
months. Twenty-eight patients (60.8%) had at least 1 rare variant
within the 40 ALS genes and 9 (19.5%) had 2 or more rare variants
(Supplementary Table 3).3.3. Novel and rare variant identiﬁcations
Of the 40 genes examined, novel or rare variants (MAF 0.001)
were found in 21 genes. Thirty-nine mis-sense variants, occurring
in 52 alleles, were identiﬁed. Nine novel variants that have not been
described in the ExAC (Table 2) occurred in 10 SALS patients. Five
patients with a novel variant (VCP p.G157R, TARDBP p.G298S,
TARDBP p.M337V or ARHGEF2 p.G1029W) had no additional vari-
ants, suggesting a possible causal effect of these variants in ALS.
Excluding the SOD1 mutation, 5 (13.2%) and 3 (7.9%) of the
remaining 38 rare variants have been previously reported in ALSdb
(http://alsdb.org/) and ALSoD (http://alsod.iop.kcl.ac.uk/) (Abel
et al., 2012) databases, respectively. No variants were found to be
signiﬁcantly associated with survival probability at the variant or
gene level.
The most frequently found variant occurred in NEK1 (p.P287A)
in 1 FALS and 2 SALS patients (1 with short survival and 2 with long
survival). A rare variant in DAO (p.P103L) was found in 2 FALS pa-
tients (F19 and F21), both with a survival <12 months. Two rarevariants were found in ITPR2 in 2 SALS patients (p.M2443T,
p.V1952A), both with a survival <18 months. A novel variant in
TARDBP (p.G298S) was shared by 2 SALS patients (MND19 and
MND40) and both survived <18 months. Another patient (MND4)
with long survival (164 months) had a different rare variant in
TARDBP (p.M337V). Patients sharing the same rare variants had pi-
hat values ranging from 0 to 0.022, indicating that they are likely to
be genetically independent (Supplementary Table 4).3.4. Effect of variant burden on survival
FALS patients with survival of less than a year all had additional
rare variants. The patient (F19) with the shortest survival had the
highest number of rare variants. These observations suggested that
the burden of rare variants may have an effect on survival, with
each additional variant reducing survival probability. Combining
FALS and SALS patients, we found that higher variant burden is
associated with lower survival probability (log-rank test X2 (2,
N ¼ 54) ¼ 13.2, p ¼ 0.00137, Fig. 1). Patients with 2 or more rare
variants had reduced survival probability compared with patients
with 0 or 1 variant (log-rank test X2 (1, N¼ 54)¼ 13.1, p¼ 0.00029).
At 15 months after symptom onset, only 33% (4/12) patients with 2
or more variants were alive without requiring ventilator support,
whereas 86% (36/42) of patients with 0 or 1 rare variant were alive.
We also performed survival analysis on SALS patients only, with
Table 3
Rare variant association for ALS and control
Variant type RV burden ALS (N ¼ 54) Control (N ¼ 699) Odds ratio (95% CI) p value (CMCFisher) p value (MB)
Synonymous RV ¼ 0 31 425 1.15 (0.63e2.09) 0.666 0.055
RV 1 23 274
Nonsynonymous RV ¼ 0 18 356 1.91 (1.03e3.61) 0.033* 0.004**
RV 1 36 343
Signiﬁcance Code: *p < 0.05, **p < 0.005.
Key: ALS, amyotrophic lateral sclerosis; CMCFisher, Collapsing and combine rare variants followed by Fisher’s exact test; MB, Upweight rare variant using inverse frequency
from controls by Madsen-Browning; OR, odds ratio; RV, rare variant.
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only included patients who were intubated or who had died as
reaching the endpoint, the result was also similar (log-rank test
p ¼ 0.00027).
After adjusting for age of onset, sex, inheritance (sporadic or
familial), and treatment with riluzole, rare variant burden remains
to be associated with survival, with each additional rare variant
increasing the risk of death/ventilator dependence by 60% (Cox
regression, p ¼ 0.0097). Bulbar onset increases the hazard risk of
death/ventilator dependence by 48% compared with spinal onset
(Cox regression, p ¼ 0.033).
3.5. Effect of rare variants on risk of developing ALS
Next, we examined if the presence of rare variants in our gene set
contributes also to the risk of developing ALS. Principal component
analysis for common variants (MAF >5%) conﬁrmed that ALS pa-
tients and healthy controls had similar genetic background
(Supplementary Fig. 2). Of 54 patients, 35 (65%) had at least 1 non-
synonymous rare variant among the 40 selected ALS genes, with an
average rare variant burden of 0.96, which is higher than the 0.68 in
controls (odds ratio 1.91, 95% CI 1.03e3.61, see Table 3). Rare variant
burden was associated with ALS (CMCFisher, p-value ¼ 0.033;
Madsen-Browning, p-value ¼ 0.0041). The sequence kernel associ-
ation test by SKAT-O, which was designed to improve power for a
mixed set of risk and protective variants, was not signiﬁcant (p-value
0.094), implying that the rare variants identiﬁed in our study had
predominantly deleterious effects in ALS patients.
4. Discussion
The clinical diagnosis of ALS relies on features of upper and
lower motor neuron degeneration. Patients demonstrate high
phenotypic variability, suggesting that ALS is a heterogeneous
disorder. About 20 genes have been identiﬁed as genetic causes of
FALS. Some phenotypic correlations have been made based on the
speciﬁc genetic mutation, but identiﬁcation of causal mutation re-
mains difﬁcult as most families have a small number of affected
individuals with wide phenotypic variability (Yamashita and Ando,
2015). Furthermore, about 30%e50% of families have nomutation in
any of the known ALS genes. Clearly, a notable genetic component
contributing to the development and clinical course of ALS, even in
the relatively more homogeneous FALS patients, remains unknown.
Our ALS gene list consists of genes that have been reported as
causative or susceptibility genes in the literature. There is evidence
that the frequencies of genetic mutations in Asian ALS patients are
different from those in patients of European ancestry. For example,
repeat expansion in C9ORF72 is the most common genetic mutation
in Caucasian ALS patients but is rare in Asians; conversely, SOD1
mutations are more common in Asians (Kim et al., 2016; Nakamura
et al., 2016; Soong et al., 2014). For this study, we have included
genes that are commonly mutated in Asian ALS patients.
In our 8 FALS patients sharing the same SOD1 mutation, there
was wide variability in survival. Therefore, we looked for additionalgenetic variants which may explain this variability. We observed
that FALS patients with additional rare variants had shorter sur-
vival. Combining FALS and SALS patients, we conﬁrmed that pa-
tients with 2 or more variants had shorter survival, suggesting an
accumulative effect of rare genetic variants on reducing survival
probability. This was conﬁrmed by gene set analysis, which showed
that variant burden within these 40 ALS genes was associated with
survival probability.
We included FALS patients in the gene set association analyses
(Table 3) as there is no evidence that familial forms of ALS are
clinically different from sporadic ones. For the survival analysis,
apart from F19 and F21 who were siblings, and F204 who was a
cousin (Supplementary Fig. 1), all the other FALS patients had low
pi-hat values indicating that they are genetically independent.
More importantly, if we exclude all FALS patients, the survival
analysis is still signiﬁcant (log-rank sum test p ¼ 0.004).
Bulbar onset increased risk of ventilator dependence or death by
47% compared with spinal onset (p ¼ 0.03). Notably, rare variant
burden had an even larger effect, with each additional rare variant
increasing the risk of ventilator dependence/death by 60%
(p¼ 0.0098). The Kaplan-Meier survival curve showed that patients
with 2 or more variants had reduced survival compared with pa-
tients with 0 or 1 variant (p ¼ 0.0003). Although no individual gene
or variant is associated with survival, rare variant burden has a
contribution to shorter survival, supporting an oligogenic basis in
the progression of ALS.
We also showed in this study that ALS patients more often had
rare variants within the 40 ALS genes than healthy controls. This
suggests that deleterious variants across a set of biologically rele-
vant genes may be responsible for the development of ALS. Our
ﬁndings are in accordance with another study which showed that
there was a signiﬁcant enrichment of deleterious rare or novel al-
leles in ALS patients compared with controls, and that 60% of SALS
patients had rare or novel variants in 169 ALS genes (Couthouis
et al., 2014). With fewer candidate genes, we showed that 60.8%
of SALS had at least 1% and 19.5% had 2 or more rare variants. This
observation conﬁrmed the importance of these 40 ALS risk genes in
disease etiology.
In a large-scale WES study, DAO was found to correlate with
survival time (Cirulli et al., 2015). In our study, rare variants in DAO
were identiﬁed in 2 FALS patients and 1 SALS patient, all with short
survival of less than 1 year. Similarly, we found 2 rare variants in
ITPR2 in 2 SALS patients, both with short survival. Our ﬁndings
suggest that DAO and ITPR2may be important in modifying disease
course and deserve further studies. We also conﬁrmed the impor-
tance of NEK1 and TBK1, 2 recently implicated ALS genes, as variants
in both genes have been identiﬁed in our ALS patients. Although no
single gene achieved genome-wide signiﬁcance, after Bonferroni
correction for 40 candidate genes, we found that TARDBP was
associated with ALS (CMCFisherExact, p-value ¼ 0.00002; Madsen-
Browning permutations, p-value ¼ 0.00004), as were C9ORF72
(SKAT-O, p ¼ 0.00032) and DAO (SKAT-O, p ¼ 0.0011).
Oligogenic inheritance of ALS has been proposed based on ob-
servations of familial and sporadic patients with mutations in 2 ALS
S.Y.-Y. Pang et al. / Neurobiology of Aging 58 (2017) 238.e9e238.e15 238.e14genes (Lattante et al., 2012; van Blitterswijk et al., 2012). An earlier
study which examined 17 ALS genes in ALS patients showed that
27.8% of SALS patients had 1 or more rare variants (Cady et al.,
2015). Looking at the exons of these 17 genes in our patients, we
saw a comparable proportion (30.4%) with 1 or more rare variants.
The previous study showed no association between rare variant
burden and disease duration. In contrast, using our list of 40 genes,
with a smaller sample size, we showed that rare variant burdenwas
associated with reduced survival. This is likely because our
expanded gene list conferred more power to detect associations
between clinical features and rare variant burden.
Genome-wide association studies have estimated that common
genetic variants account for 8.5%e12% of heritability of ALS (Fogh
et al., 2014; van Rheenen et al., 2016). Using genome-wide com-
plex trait analysis looking at common variants in ALS patients,
another study further increased the heritability estimate to 21%
(Keller et al., 2014), while twin studies showed ALS heritability to be
around 61% (Al-Chalabi et al., 2010). The “missing heritability” is
likely due to rare variants, and our study conﬁrmed that a notable
proportion of SALS patients carried rare variants in ALS risk and
susceptibility genes.
Just as we have shown that rare variants can inﬂuence survival
in ALS, common variants may also play a role. A genome-wide as-
sociation study carried out in patients from Europe and the United
States identiﬁed common variants in CAMTA1 to be associated with
survival (Fogh et al., 2016). In our 54 patients, 5 carried the rare
nonsynonymous variant in CAMTA1: F21, F310, and MND64 carried
the same rare variant (p.V949L) and had survival of 11, 37, and
3 months, respectively. F331 carried a p.M401I variant and survived
for 74 months, whereas MND59 carried a p.A1407G variant and
survived for 31 months. All 3 variants are located more than 630kb
away from the reported common variant (rs2412208). Further
studies may elucidate the role of CAMTA1 in modifying the disease
course of ALS.
There are some limitations to our study. Our sample size is small.
However, because all patients were seen in a single center, we have
detailed phenotype information enabling analysis for genotype-
phenotype correlation. We only examined the exons of 40 genes
for nonsynonymous mis-sense mutations. Repeat expansions, var-
iants located in noncoding regions, and copy number variations
would not be detected in our study. We did not screen for the
hexanucleotide repeat expansion in C9ORF72, the most common
genetic cause of ALS in the West, but this mutation is exceedingly
rare in Chinese, Koreans, and Japanese (He et al., 2015; Kim et al.,
2016; Nakamura et al., 2016). Similarly, repeat expansions in
ATXN2 and copy number variations in SMN1 were not included in
our study. Although it is not known if nonsynonymous single
nucleotide variants in C9ORF72 and ATXN2 cause ALS, we never-
theless included these genes in our analysis to look for the presence
of variants in the exons of these genes in ALS patients. In fact, a
recent study which included 469 Japanese ALS patients identiﬁed
an single nucleotide variant in C9ORF72 in 1 patient, while no
repeat expansion was detected (Nakamura et al., 2016). There are
various models which provide pathogenicity predictions of variants
(Supplementary Table 5), but different models give different pre-
dictions and the results are not always consistent. Hence, in our
analysis, we treated all rare variants equally and did not take into
account whether some variants may be more deleterious than
others. Survival analysis suggests that inheritance (familial versus
sporadic) did not inﬂuence survival. FALS patient with only the
SOD1 mutation had similar survival as SALS patients with 0 or 1
variant. Rather, it is the burden of rare variants that was found to
affect survival.
While increasing number of genes have been implicated in ALS,
individual gene variants are so rare that even studies with largesample sizes often cannot deﬁnitively conﬁrm causal effect or as-
sociationwith clinical features. The ﬁndings from our study suggest
that development and progression of ALS may involve more than 1
genetic mutation. A previous study showed that there was a linear
relationship between log incidence and log age in ALS in 5 pop-
ulations, consistent with a multistep model (Al-Chalabi et al., 2014).
This would be in agreement with our ﬁnding of an oligogenic in-
ﬂuence on the prognosis of ALS, with each additional rare variant
increasing the risk of mortality, suggesting that development and
progression of ALS is indeed a multi-hit process. Our ﬁndings
highlight the importance of looking into the possible interaction
among known ALS genes which could collectively affect disease
progression. Cellular pathways and potential pathogenic mecha-
nisms, such as disruption of protein degradation and RNA meta-
bolism defects, are already emerging from the plethora of genetic
factors so far identiﬁed (Taylor et al., 2016), with implications on
possible therapeutic targets. Further studies in elucidating cellular
pathways shared by our 40 ALS genes may identify therapeutic
targets to prolong survival. Furthermore, a potential clinical appli-
cation of our results is to predict and stratify survival in ALS patients
using their genetic proﬁle, which may be useful in future inter-
ventional trials to more accurately measure the efﬁcacy of treat-
ment in prolonging survival.
Disclosure statement
The authors report no conﬂict of interest.
Acknowledgements
The authors would like to thank Timothy Shin Heng Mak, PhD,
Centre for Genomic Sciences, University of Hong Kong and Prof.
Hung Fat Tse, MD, PhD, Department of Medicine, University of Hong
Kong who provided sequencing data from controls.
This work was supported by Liu Po Shan/Dr Vincent Liu
Endowment Fund for Motor Neurone Disease, the Henry G. Leong
Professorship in Neurology, the Donation Fund for Neurology
Research, Hong Kong Research Grants Council grants AoE/M-04/
04&T12-708/12-N, European Community Seventh Framework
Programme Grant on European Network of National Schizophrenia
Networks Studying Gene-Environment Interactions (EU-GEI), the
HKU Seed Funding Programme for Basic Research 201411159172,
Health and the Medical Research Fund - Full Grant 01121436.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.neurobiolaging.
2017.06.007.
References
Abel, O., Powell, J.F., Andersen, P.M., Al-Chalabi, A., 2012. ALSoD: a user-friendly
online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum.
Mutat. 33, 1345e1351.
Al-Chalabi, A., Calvo, A., Chio, A., Colville, S., Ellis, C.M., Hardiman, O., Heverin, M.,
Howard, R.S., Huisman, M.H., Keren, N., Leigh, P.N., Mazzini, L., Mora, G.,
Orrell, R.W., Rooney, J., Scott, K.M., Scotton, W.J., Seelen, M., Shaw, C.E.,
Sidle, K.S., Swingler, R., Tsuda, M., Veldink, J.H., Visser, A.E., van den Berg, L.H.,
Pearce, N., 2014. Analysis of amyotrophic lateral sclerosis as a multistep process:
a population-based modelling study. Lancet Neurol. 13, 1108e1113.
Al-Chalabi, A., Fang, F., Hanby, M.F., Leigh, P.N., Shaw, C.E., Ye, W., Rijsdijk, F., 2010.
An estimate of amyotrophic lateral sclerosis heritability using twin data.
J. Neurol. Neurosurg. Psychiatry 81, 1324e1326.
Brooks, B.R., Miller, R.G., Swash, M., Munsat, T.L. World Federation of Neurology
Research Group on Motor Neuron Diseases, 2000. El Escorial revisited: revised
criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral
Scler. Other Mot. Neuron Disord 1, 293e299.
S.Y.-Y. Pang et al. / Neurobiology of Aging 58 (2017) 238.e9e238.e15238.e15Cady, J., Allred, P., Bali, T., Pestronk, A., Goate, A., Miller, T.M., Mitra, R.D., Ravits, J.,
Harms, M.B., Baloh, R.H., 2015. ALS onset is inﬂuenced by the burden of rare
variants in known ALS genes. Ann. Neurol. 77, 100e113.
Chang, C.C., Chow, C.C., Tellier, L.C.A.M., Vattikuti, S., Purcell, S.M., Lee, J.J., 2015.
Second-generation PLINK: rising to the challenge of larger and richer datasets.
GigaScience 4, 7.
Cirulli, E.T., Lasseigne, B.N., Petrovski, S., Sapp, P.C., Dion, P.A., Leblond, C.S.,
Couthouis, J., Lu, Y.F., Wang, Q., Krueger, B.J., Ren, Z., Keebler, J., Han, Y., Levy, S.E.,
Boone, B.E., Wimbish, J.R., Waite, L.L., Jones, A.L., Carulli, J.P., Day-Williams, A.G.,
Staropoli, J.F., Xin, W.W., Chesi, A., Raphael, A.R., McKenna-Yasek, D., Cady, J.,
Vianney de Jong, J.M., Kenna, K.P., Smith, B.N., Topp, S., Miller, J., Gkazi, A., FALS
Sequencing Consortium, Al-Chalabi, A., van den Berg, L.H., Veldink, J., Silani, V.,
Ticozzi, N., Shaw, C.E., Baloh, R.H., Appel, S., Simpson, E., Lagier-Tourenne, C.,
Pulst, S.M., Gibson, S., Trojanowski, J.Q., Elman, L., McCluskey, L., Grossman, M.,
Shneider, N.A., Chung, W.K., Ravits, J.M., Glass, J.D., Sims, K.B., Van Deerlin, V.M.,
Maniatis, T., Hayes, S.D., Ordureau, A., Swarup, S., Landers, J., Baas, F., Allen, A.S.,
Bedlack, R.S., Harper, J.W., Gitler, A.D., Rouleau, G.A., Brown, R., Harms, M.B.,
Cooper, G.M., Harris, T., Myers, R.M., Goldstein, D.B., 2015. Exome sequencing in
amyotrophic lateral sclerosis identiﬁes risk genes and pathways. Science 347,
1436e1441.
Couthouis, J., Raphael, A.R., Daneshjou, R., Gitler, A.D., 2014. Targeted exon capture
and sequencing in sporadic amyotrophic lateral sclerosis. PLoS Genet. 10,
e1004704.
Cronin, S., Hardiman, O., Traynor, B.J., 2007. Ethnic variation in the incidence of ALS:
a systematic review. Neurology 68, 1002e1007.
Finsterer, J., Burgunder, J.M., 2014. Recent progress in the genetics of motor neuron
disease. Eur. J. Med. Genet. 57, 103e112.
Fogh, I., Lin, K., Tiloca, C., Rooney, J., Gellera, C., Diekstra, F.P., Ratti, A., Shatunov, A.,
van Es, M.A., Proitsi, P., Jones, A., Sproviero, W., Chiò, A., McLaughlin, R.L.,
Sorarù, G., Corrado, L., Stahl, D., Del Bo, R., Cereda, C., Castellotti, B., Glass, J.D.,
Newhouse, S., Dobson, R., Smith, B.N., Topp, S., van Rheenen, W., Meininger, V.,
Melki, J., Morrison, K.E., Shaw, P.J., Leigh, P.N., Andersen, P.M., Comi, G.P.,
Ticozzi, N., Mazzini, L., D’Alfonso, S., Traynor, B.J., Van Damme, P.,
Robberecht, W., Brown, R.H., Landers, J.E., Hardiman, O., Lewis, C.M., van den
Berg, L.H., Shaw, C.E., Veldink, J.H., Silani, V., Al-Chalabi, A., Powell, J., 2016.
Association of a locus in the CAMTA1 gene with survival in patients with spo-
radic amyotrophic lateral sclerosis. JAMA Neurol. 73, 812e820.
Fogh, I., Ratti, A., Gellera, C., Lin, K., Tiloca, C., Moskvina, V., Corrado, L., Sorarù, G.,
Cereda, C., Corti, S., Gentilini, D., Calini, D., Castellotti, B., Mazzini, L., Querin, G.,
Gagliardi, S., Del Bo, R., Conforti, F.L., Siciliano, G., Inghilleri, M., Saccà, F.,
Bongioanni, P., Penco, S., Corbo, M., Sorbi, S., Filosto, M., Ferlini, A., Di
Blasio, A.M., Signorini, S., Shatunov, A., Jones, A., Shaw, P.J., Morrison, K.E.,
Farmer, A.E., Van Damme, P., Robberecht, W., Chiò, A., Traynor, B.J., Sendtner, M.,
Melki, J., Meininger, V., Hardiman, O., Andersen, P.M., Leigh, N.P., Glass, J.D.,
Overste, D., Diekstra, F.P., Veldink, J.H., van Es, M.A., Shaw, C.E., Weale, M.E.,
Lewis, C.M., Williams, J., Brown, R.H., Landers, J.E., Ticozzi, N., Ceroni, M.,
Pegoraro, E., Comi, G.P., D’Alfonso, S., van den Berg, L.H., Taroni, F., Al-Chalabi, A.,
Powell, J., Silani, V. SLAGEN Consortium and Collaborators, 2014. A genome-
wide association meta-analysis identiﬁes a novel locus at 17q11.2 associated
with sporadic amyotrophic lateral sclerosis. Hum. Mol. Genet. 23, 2220e2231.
Fong, G.C., Cheng, T.S., Lam, K., Cheng, W.K., Mok, K.Y., Cheung, C.M., Chim, C.S.,
Mak, W., Chan, K.H., Tsang, K.L., Kwan, M.C., Tsoi, T.H., Cheung, R.T., Ho, S.L.,
2005. An epidemiological study of motor neuron disease in Hong Kong.
Amyotroph. Lateral Scler. Other Mot. Neuron Disord 6, 164e168.
Fong, G.C.Y., Kwok, K.H.H., Song, Y.Q., Cheng, T.S., Ho, P.W., Chu, A.C., Kung, M.H.,
Chan, K.H., Mak, W., Cheung, R.T., Ramsden, D.B., Ho, S.L., 2006. Clinical phe-
notypes of a large Chinese multigenerational kindred with autosomal dominant
familial ALS due to Ile149Thr SOD1 gene mutation. Amyotroph. Lateral Scler. 7,
142e149.
He, J., Tang, L., Benyamin, B., Shah, S., Hemani, G., Liu, R., Ye, S., Liu, X., Ma, Y.,
Zhang, H., Cremin, K., Leo, P., Wray, N.R., Visscher, P.M., Xu, H., Brown, M.A.,
Bartlett, P.F., Mangelsdorf, M., Fan, D., 2015. C9orf72 hexanucleotide repeat ex-
pansions in Chinese sporadic amyotrophic lateral sclerosis. Neurobiol. Aging 36,
2660.e1e2660.e8.
Hsu, J.S., Kwan, J.S., Pan, Z., Garcia-Barcelo, M.M., Sham, P.C., Li, M., 2016. Inheri-
tance-mode speciﬁc pathogenicity prioritization (ISPP) for human protein
coding genes. Bioinformatics 32, 3065e3071.
Ionita-Laza, I., Lee, S., Makarov, V., Buxbaum, J.D., Lin, X., 2013. Sequence kernel
association tests for the combined effect of rare and common variants. Am. J.
Hum. Genet. 92, 841e853.
Keller, M.F., Ferrucci, L., Singleton, A.B., Tienari, P.J., Laaksovirta, H., Restagno, G.,
Chio, A., Traynor, B.J., Nalls, M.A., 2014. Genome-wide analysis of the heritability
of amyotrophic lateral sclerosis. JAMA Neurol. 71, 1123e1134.
Kenna, K.P., McLaughlin, R.L., Burne, S., Elamin, M., Heverin, M., Kenny, E.M.,
Cormican, P., Morris, D.W., Donaghy, C.G., Bradley, D.G., Hardiman, O., 2013.
Delineating the genetic heterogeneity of ALS using targeted high-throughput
sequencing. J. Med. Genet. 50, 776e783.
Kim, H.J., Oh, K.W., Kwon, M.J., Oh, S.I., Park, J.S., Kim, Y.E., Choi, B.O., Lee, S., Ki, C.S.,
Kim, S.H., 2016. Identiﬁcation of mutations in Korean patients with amyotrophic
lateral sclerosis using multigene panel testing. Neurobiol. Aging 37,
209.e9e209.e16.Lattante, S., Conte, A., Zollino, M., Luigetti, M., Del Grande, A., Marangi, G.,
Romano, A., Marcaccio, A., Meleo, E., Bisogni, G., Rossini, P.M., Sabatelli, M., 2012.
Contribution of major amyotrophic lateral sclerosis genes to the etiology of
sporadic disease. Neurology 79, 66e72.
Leblond, C., Kaneb, H., Dion, P.A., Rouleau, G.A., 2014. Dissection of genetic
factors associated with amyotrophic lateral sclerosis. Exp. Neurol. 262 (Pt
B), 91e101.
Li, M.X., Gui, H.S., Kwan, J.S., Bao, S.Y., Sham, P.C., 2012. A comprehensive framework
for prioritizing variants in exome sequencing studies of Mendelian diseases.
Nucleic Acids Res. 40, e53.
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A.,
Garimella, K., Altshuler, D., Gabriel, S., Daly, M., DePristo, M.A., 2010. The
Genome Analysis Toolkit: a MapReduce framework for analyzing next-
generation DNA sequencing data. Genome Res. 20, 1297e1303.
Nakamura, R., Sone, J., Atsuta, N., Tohnai, G., Watanabe, H., Yokoi, D., Nakatochi, M.,
Watanabe, H., Ito, M., Senda, J., Katsuno, M., Tanaka, F., Li, Y., Izumi, Y.,
Morita, M., Taniguchi, A., Kano, O., Oda, M., Kuwabara, S., Abe, K., Aiba, I.,
Okamoto, K., Mizoguchi, K., Hasegawa, K., Aoki, M., Hattori, N., Tsuji, S.,
Nakashima, K., Kaji, R., Sobue, G. Japanese Consortium for Amyotrophic Lateral
Sclerosis Research (JaCALS), 2016. Next generation sequencing of 28 ALS-related
genes in a Japanese ALS cohort. Neurobiol. Aging 39, 219.e1e219.e8.
Ng, M.C., Ho, J.T., Ho, S.L., Lee, R., Li, G., Cheng, T.S., Song, Y.Q., Ho, P.W., Fong, G.C.,
Mak, W., Chan, K.H., Li, L.S., Luk, K.D., Hu, Y., Ramsden, D.B., Leong, L.L., 2008.
Abnormal diffusion tensor in non-symptomatic familial amyotrophic lateral
sclerosis with a causative superoxide dismutase 1 mutation. J. Magn. Reson.
Imaging 27, 8e13.
Renton, A.E., Chio, A., Traynor, B.J., 2014. State of play in amyotrophic lateral scle-
rosis genetics. Nat. Neurosci. 17, 17e23.
Soong, B.W., Lin, K.P., Guo, Y.C., Lin, C.C., Tsai, P.C., Liao, Y.C., Lu, Y.C., Wang, S.J.,
Tsai, C.P., Lee, Y.C., 2014. Extensive molecular genetic survey of Taiwanese pa-
tients with amyotrophic lateral sclerosis. Neurobiol. Aging 35,
2423.e1e2423.e16.
Swinnen, B., Robberecht, W., 2014. The phenotypic variability of amyotrophic lateral
sclerosis. Nat. Rev. Neurol. 10, 661e670.
Taylor, J.P., Brown Jr., R.H., Cleveland, D.W., 2016. Decoding ALS: from genes to
mechanism. Nature 539, 197e206.
van Blitterswijk, M., van Es, M.A., Hennekam, E.A.M., Dooijes, D., van Rheenen, W.,
Medic, J., Bourque, P.R., Schelhaas, H.J., van der Kooi, A.J., de Visser, M., de
Bakker, P.I., Veldink, J.H., van den Berg, L.H., 2012. Evidence for an oligogenic
basis of amyotrophic lateral sclerosis. Hum. Mol. Genet. 21, 3776e3784.
van Rheenen, W., Shatunov, A., Dekker, A.M., McLaughlin, R.L., Diekstra, F.P.,
Pulit, S.L., van der Spek, R.A., Võsa, U., de Jong, S., Robinson, M.R., Yang, J.,
Fogh, I., van Doormaal, P.T., Tazelaar, G.H., Koppers, M., Blokhuis, A.M.,
Sproviero, W., Jones, A.R., Kenna, K.P., van Eijk, K.R., Harschnitz, O.,
Schellevis, R.D., Brands, W.J., Medic, J., Menelaou, A., Vajda, A., Ticozzi, N., Lin, K.,
Rogelj, B., Vrabec, K., Ravnik-Glavac, M., Koritnik, B., Zidar, J., Leonardis, L.,
Groselj, L.D., Millecamps, S., Salachas, F., Meininger, V., de Carvalho, M., Pinto, S.,
Mora, J.S., Rojas-García, R., Polak, M., Chandran, S., Colville, S., Swingler, R.,
Morrison, K.E., Shaw, P.J., Hardy, J., Orrell, R.W., Pittman, A., Sidle, K., Fratta, P.,
Malaspina, A., Topp, S., Petri, S., Abdulla, S., Drepper, C., Sendtner, M., Meyer, T.,
Ophoff, R.A., Staats, K.A., Wiedau-Pazos, M., Lomen-Hoerth, C., Van
Deerlin, V.M., Trojanowski, J.Q., Elman, L., McCluskey, L., Basak, A.N., Tunca, C.,
Hamzeiy, H., Parman, Y., Meitinger, T., Lichtner, P., Radivojkov-Blagojevic, M.,
Andres, C.R., Maurel, C., Bensimon, G., Landwehrmeyer, B., Brice, A., Payan, C.A.,
Saker-Delye, S., Dürr, A., Wood, N.W., Tittmann, L., Lieb, W., Franke, A.,
Rietschel, M., Cichon, S., Nöthen, M.M., Amouyel, P., Tzourio, C., Dartigues, J.F.,
Uitterlinden, A.G., Rivadeneira, F., Estrada, K., Hofman, A., Curtis, C., Blauw, H.M.,
van der Kooi, A.J., de Visser, M., Goris, A., Weber, M., Shaw, C.E., Smith, B.N.,
Pansarasa, O., Cereda, C., Del Bo, R., Comi, G.P., D’Alfonso, S., Bertolin, C.,
Sorarù, G., Mazzini, L., Pensato, V., Gellera, C., Tiloca, C., Ratti, A., Calvo, A.,
Moglia, C., Brunetti, M., Arcuti, S., Capozzo, R., Zecca, C., Lunetta, C., Penco, S.,
Riva, N., Padovani, A., Filosto, M., Muller, B., Stuit, R.J., PARALS Registry SLALOM
Group SLAP Registry FALS Sequencing Consortium SLAGEN Consortium NNIPPS
Study Group, Blair, I., Zhang, K., McCann, E.P., Fiﬁta, J.A., Nicholson, G.A.,
Rowe, D.B., Pamphlett, R., Kiernan, M.C., Grosskreutz, J., Witte, O.W., Ringer, T.,
Prell, T., Stubendorff, B., Kurth, I., Hübner, C.A., Leigh, P.N., Casale, F., Chio, A.,
Beghi, E., Pupillo, E., Tortelli, R., Logroscino, G., Powell, J., Ludolph, A.C.,
Weishaupt, J.H., Robberecht, W., Van Damme, P., Franke, L., Pers, T.H.,
Brown, R.H., Glass, J.D., Landers, J.E., Hardiman, O., Andersen, P.M., Corcia, P.,
Vourc’h, P., Silani, V., Wray, N.R., Visscher, P.M., de Bakker, P.I., van Es, M.A.,
Pasterkamp, R.J., Lewis, C.M., Breen, G., Al-Chalabi, A., van den Berg, L.H.,
Veldink, J.H., 2016. Genome-wide association analyses identify new risk vari-
ants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet.
48, 1043e1048.
Yamashita, S., Ando, Y., 2015. Genotype-phenotype relationship in hereditary
amyotrophic lateral sclerosis. Transl. Neurodegener. 4, 13.
Yang, J., Lee, S.H., Goddard, M.E., Visscher, P.M., 2011. GCTA: a tool for genome-wide
complex trait analysis. Am. J. Hum. Genet. 88, 76e82.
Zhan, X., Hu, Y., Li, B., Abecasis, G.R., Liu, D.J., 2016. RVTESTS: an efﬁcient and
comprehensive tool for rare variant association analysis using sequence data.
Bioinformatics 32, 1423e1426.
